Project Grant R43TR004551
Award Date
1/1/24
Completion Date
12/31/24
Dollars Obligated
$339K
Federal Agency
National Center for Advancing Translational Sciences
Awardee
Mabswitch Inc. (MZ15MPUFBHN9)
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Center for Advancing Translational Sciences (NCATS) awarded a $275,000 Project Grant (CFDA 93.350) to Nectagen Inc. to develop bioprocess-compatible, second-generation nanoclamp affinity resins for the efficient purification of plasma-based therapeutic proteins. The goal is to identify panels of nanoclamps to 5 industrially relevant plasma-based therapeutics, select lead candidates, and optimize the resins for maximum recovery and purity from plasma samples. This project aims to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,958 to Mabswitch Inc., a minority-owned small business, to assess the feasibility of regulating the activation, effector functions, and cytokine release of chimeric antigen receptor (CAR) T-cell therapies. The project aims to develop a "switchable affinity CAR" (SAEFCAR) that can be controlled by an exogenously administered ligand, potentially mitigating the toxicity...
The National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, has awarded a $331,034 Project Grant to Vector Surgical LLC to develop the Gene Therapy Catheter (GTC) - an electrical pulsing device designed to enhance the delivery of adeno-associated virus (AAV) gene therapy to the liver. The GTC aims to improve the efficiency and safety of liver-directed gene therapies by combining local delivery with electrical pulsing and a double-balloon system to isolate the...
The National Center for Advancing Translational Sciences (NCATS), under the CFDA 93.350 Federal Grant Program, awarded a $230,499 Project Grant to Vindhya Data Science Inc. on July 15, 2024. The grant supports the development of BIOCLIN, a precision medicine software platform designed to enable RNA sequencing-based biomarker clinical trials. The project aims to (1) conduct user research to understand investigator needs for running RNA sequencing biomarker trials and develop a roadmap for the...
The National Center for Advancing Translational Sciences (NCATS), through its CFDA 93.350 Federal Grant Program, awarded a $294,541 Project Grant to Cellular Vehicles Inc. on June 1, 2024. The purpose of this award is to develop an automated system for producing and delivering cell-laden hydrogel therapies. The project aims to create a novel, standardized process for formulating, encapsulating, and directly injecting cell-laden hydrogels into diseased tissues. This is intended to improve the...
The National Center for Advancing Translational Sciences (NCATS) awarded a $1,077,369 Project Grant (CFDA 93.350) to Captis Diagnostics Inc., a Pittsburgh-based small disadvantaged business, to develop and commercialize a proprietary Lipid Nanoprobe (LNP) system for rapid, efficient isolation of extracellular vesicles (EVs) from various bodily fluids. This 2-year award aims to further optimize the LNP technology for EV enrichment from plasma, serum, urine, and saliva, and evaluate, validate, and...
The National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, has awarded a $324,962 Project Grant to Tetmedical, Inc. to develop a technology for rapid, point-of-care and at-home testing of liver enzyme levels. The goal is to enable convenient and timely monitoring of drug-induced liver injury (DILI) and other sources of liver damage. The project aims to optimize tethered enzyme assays for detecting aspartate aminotransferase (AST) and alanine aminotransferase (ALT),...
This federal Project Grant award, valued at $540,524 and effective from March 1, 2025 to February 28, 2029, was provided by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program. The primary objective of this award is to develop an enhanced RNA switch technology based on the T3H38 ribozyme, which can enable precise dose control and temporal regulation...
Codomax Inc., a biotechnology company, received a $350,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA Program 93.350. The funding supports Codomax's research and development to optimize antibody production in Chinese Hamster Ovary (CHO) cells using its proprietary EPI-MAX technology platform. The project aims to enhance heavy and light chain expression by analyzing tRNA systems that limit antibody production and re-engineering the CREB1...
The National Institutes of Health's National Center for Advancing Translational Sciences (NCATS) awarded a $288,240 Project Grant (CFDA 93.350) to the La Jolla Institute for Immunology. The grant, titled "Linking Specific Phosphorylation Events to Distinct Transcriptional States", aims to develop an innovative data-driven technology solution integrating global, temporally-resolved transcriptomic and phosphoproteomic data with statistical modeling. This will systematically identify...